RNA-seq detects pharmacological inhibition of Epstein-Barr virus late transcription during spontaneous reactivation

An T. Phan\textsuperscript{a,1}, Delsy M. Martinez\textsuperscript{a,b}, JJ L. Miranda\textsuperscript{a,b,⁎}

\textsuperscript{a} Gladstone Institute of Virology and Immunology, San Francisco, CA 94158, USA
\textsuperscript{b} Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94143, USA

A B S T R A C T

The stepwise and sequential expression of viral genes underlies progression of the infectious life cycle. The Epstein-Barr virus (EBV) is both a tractable model for elucidating principles of transcription as well as a global health threat. We describe an experimental protocol and bioinformatics pipeline for functional identification of EBV true late genes, the last step of transcription prior to virion packaging and egress. All data have been uploaded to the Gene Expression Omnibus under accession code GSE96689. The key improvement over previous approaches is leveraging the sensitivity of RNA-seq to detect gene expression changes during spontaneous reactivation.

Specifications

| Organism/cell line/tissue | GM12878 lymphoblastoid and MutuI Burkitt lymphoma cell lines |
|---------------------------|---------------------------------------------------------------|
| Sex                       | GM12878: female, MutuI: male                                   |
| Sequencer/array type      | Illumina HiSeq                                                  |
| Data format               | Raw FASTQ and analyzed wig                                     |
| Experimental factors      | 200 μM acyclovir vs. vehicle                                   |
| Experimental features     | Total RNA was purified for RNA-seq library construction       |
| Consent                   | Not applicable                                                 |
| Sample source location    | Not applicable                                                 |

1. Direct link to deposited data

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96689

2. Introduction

Temporal control of Epstein-Barr virus (EBV) transcription drives transitions between different stages of the pathogenic life cycle [1]. In a manner similar to other herpesviruses, EBV lytic transcription proceeds via a sequential cascade: cellular signaling induces expression of immediate-early genes, immediate-early proteins transactivate early genes, early proteins promote DNA replication, DNA replication allows expression of late genes, and late gene proteins assemble virions for egress. No gold standard experiment, however, yet exists where the identities of EBV true late genes have been determined based on dependence for lytic DNA replication. Assignment as a late gene has generally been based on putative function or homology to other herpes proteins [1,2]. Experimentally, one intuitive approach would be to pharmacologically inhibit the viral lytic DNA polymerase and measure transcription changes genome-wide. Previous such attempts, however, have yielded confounding results. Microarray measurements showed that phosphonoacetic acid down-regulates all EBV genes, even early transcripts [2]. In contrast, PCR assays determined that acyclovir down-regulates no EBV genes at all [3]. The two conflicting experiments both initiated lytic transcription with IgG crosslinking prior to drug treatment [4]. In an attempt to improve upon previous results, we made two technical changes. First, we inhibit spontaneous reactivation naturally observed without external induction [5] in the hope that the effect of a pharmacological inhibitor would be more detectable. Second, we leverage the sensitivity of RNA deep sequencing (RNA-seq) to measure small transcriptional changes that are less accessible to other methods.
reads and integrated only over exons spanning regions that did not overlap with another transcript based on version 6 of a published B95-8 annotation [11] (Tables 1 and 2). Regions corresponding to overlapping exons from more than one transcript were excluded from analysis. Genes were initially designated as either early or late based on known properties [2]. The differential expression significance threshold was set at a p-value < 0.05 as determined by a paired Student’s t-test. Because of the small sample size within both the early and late gene sets, p-values were not adjusted for multiple testing. Expression level differences represent the mean fold change of biological replicates. Every data set yielded ~60–120 million mapped sequences with reproducible transcriptome profiles.

4. Data description

We demonstrate here that RNA-seq detects specific inhibition of EBV late genes by acyclovir during spontaneous reactivation. Transcriptome profiles show down-regulation of select EBV transcripts. In the GM12878 lymphoblastoid cell line, 14 out of 18 presumed late genes, but only 2 out of 17 presumed early genes, decrease expression upon acyclovir treatment (Table 1). Two early genes unexpectedly increase expression. Only 3 out of 18 presumed late genes decrease expression in the MutuI Burkitt lymphoma cell line (Table 2). MutuI samples displayed more variability within experimental groups compared to GM12878 samples, contributing to the lower number of statistically significant changes. In summary, enrichment for late genes among differentially expressed transcripts in two independent cell lines validates the specificity of this approach. We present our bioinformatic pipeline and experimental protocol for colleagues to investigate other inhibitors and cell lines in building a comprehensive classification of EBV true late genes.

Conflict of interest

The authors have no potential conflicts of interest to disclose.

Acknowledgements

We thank the UCSF Center for Advanced Technology and the Gladstone Genomics Core for use of shared equipment. We are grateful to Kristin M. Keck for insightful suggestions regarding bioinformatic analysis. D.M.M. was supported by a US National Science Foundation Predoctoral Fellowship.

References

[1] E.D. Kieff, A.B. Rickinson, Epstein-Barr virus and its replication, in: D.M. Knipe, P.M. Howley (Eds.), Fields Virology, Lippincott Williams & Wilkins, Philadelphia, 2007, pp. 2603–2654.
[2] J. Yuan, E. Cabir-McFarland, B. Zhao, E. Kieff, Virus and cell RNAs expressed during Epstein-Barr virus replication, J. Virol. 80 (2006) 2548–2565.
[3] F.Z. Wang, D. Roy, E. Ginsburg, C.B. Whiteman, D.P. Stittner, J.S. Pagano, Maribavir inhibits Epstein-Barr virus transcription in addition to viral DNA replication, J. Virol. 83 (2009) 12108–12117.
[4] M.G. Tovey, G. Lenour, J. Begon-Lour, Activation of latent Epstein-Barr virus by antibody to human IgM, Nature 276 (1978) 270–272.
[5] A.T. Phan, S.G. Fernandez, J.J. Somberg, K.M. Keck, J.L. Miranda, Epstein-Barr virus latency type and spontaneous reactivation predict lytic induction levels, Biochem. Biophys. Res. Commun. 474 (2016) 71–75.
[6] E.P. Consortium, An integrated encyclopedia of DNA elements in the human genome, Nature 489 (2012) 57–74.
[7] C.D. Gregory, M. Rowe, A.B. Rickinson, Differential Epstein-Barr Virus-B cell interactions in phenotypically distinct clones of a Burkitt’s lymphoma cell line, J. Gen. Virol. 71 (Pt 7) (1990) 1481–1495.
[8] R. Langmead, C. Trapnell, M. Pop, S.L. Salzberg, Ultrafast and memory-efficient alignment of short DNA sequences to the human genome, Genome Biol. 10 (2009) R25.
[9] J.T. Robinson, H. Thorvaldsdottir, W. Winckler, M. Guttman, E.S. Lander, G. Getz, J.P. Mesirov, Integrative genomic viewer, Nat. Biotechnol. 29 (2011) 24–26.
[10] H. Thorvaldsdottir, J.T. Robinson, J.P. Mesirov, Integrative genomic viewer (IGV): high-performance genomics data visualization and exploration, Brief. Bioinform. 14 (2013) 178–192.
[11] Z. Lin, G. Xu, N. Deng, C. Taylor, D. Zhu, E.K. Flemington, Quantitative and qualitative RNA-Seq-based evaluation of Epstein-Barr virus transcription in type 1 latency Burkitt’s lymphoma cells, J. Virol. 84 (2010) 13053–13058.